MedTrace Logo

TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT07324239 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-07

No results posted yet for this study

Summary

Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.

Conditions

  • Prostatitis

Interventions

DEVICE

TECAR therapy

WINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm\*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity.

DEVICE

Sham TECAR therapy

The procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session.

Sponsors & Collaborators

  • Middle East University

    lead OTHER

Principal Investigators

  • Mohammed Saif · National institute for Gerontology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-02
Primary Completion
2026-04-01
Completion
2026-04-07

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07324239 on ClinicalTrials.gov